National Institute for Clinical Excellence (NICE) Says No to Celgene’s Bone Marrow Disease Drug Vidaza (azacitidine)

Reuters -- Britain's healthcare cost agency has recommended that Celgene's drug Vidaza, or azacitidine, should not be used in the state-run health service to treat a rare blood cancer because it is too expensive.